2nd Operationalize: Expanded Access Programs Summit West

Across the West Coast, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development, supporting patients for longer durations, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive, exception-based activity is now a visible, repeatable function - bringing heightened expectations around governance, post-trial access, sustainability, and real-world insight generation, all while ensuring patients are not delayed or disadvantaged.

The 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams, this summit brings together senior leaders across Access, Medical Affairs, Clinical Operations, Regulatory, and Clinical Supply to share how EAPs are being designed, governed, and scaled in today's environment.

Over three focused days, the summit tackles the most pressing questions facing EAP teams in 2026 - from navigating evolving U.S. and global regulatory expectations, to enabling providers and patient advocates, designing post-trial access strategies, managing long-duration and rare disease programs, and applying real-world insights without slowing access.

This is not a theoretical discussion. It is a peer-led, non-competitive forum for teams responsible for delivering access at scale - and for those shaping what Expanded Access must become next.

URL:
Tickets: https://go.evvnt.com/3532366-1?pid=154

Time: 9:00 AM - 5:00 PM

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4397.00,
Drug Developer Pricing - Conference Only: USD 3099.00,
Academic Pricing - Conference + Workshop Day: USD 3797.00,
Academic Pricing - Conference Only: USD 2699.00,
Solution Provider Pricing - Conference + Workshop Day: USD 5297.00,
Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Amelia Spinrad, Associate Director, Gilead, Annie Drelles, Senior Director, Medical Access, Global Oncology Medical Affairs, Daiichi Sankyo, Danielle Rafferty, Director, Research Grants and Expanded Access, Alkermes, Jasna Mihajlovic, Director, Integrated Evidence Generation, Genmab, Suzanne Morgan, Executive Director and Head, Market Access, Stealth Biotherapeutics, Jose Ricardo Perez, Vice President, Genitourinary Portfolio, Medical Affairs, Exelixis, Joan Clements, Chief Executive Officer, CML Buster Foundation, Kim Cohee, Executive Director, Patient Advocacy, Tenaya Therapeutics, Kirsten Hoyer, Associate Director, Ascendis Pharma, Marjan Sepassi, Vice President Medical Affairs, Clene Nanomedicine, Dawn Sullivan, Global Medical Affairs, Ultragenyx , Dennis Akkaya, Chief Commerical Officer, myTomorrows, Gerald Clements, Co-Founder and Chief Financial Officer, CML Buster Foundation, Madison Henry, Global Oncology Medical Strategy Manager, Daiichi Sankyo, Kristen Hurley, Director, US Medical Affairs, Strategy, Multiple Myeloma, Kite Pharma, Kyle Taylor, Global Oncology Medical Affairs and Clinical Trial Management Manager, Daiichi Sankyo, Nicole Gregory, Senior Director, Supply Chain, Gilead, Shobhana Natarajan, Director, Rare Disease, Medical Affairs, Patrick Stutz, Senior Associate, Clinical Trial Management, Kite Pharma